BMRN Stock BioMarin Pharmaceutical Inc.
BUY US · NasdaqGSRare-disease portfolio and strong analyst upside support attractive six-to-twelve-month appreciation potential.
Future value: $91.56 (+64.23%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Strong Buy consensus and repeated analyst Buy ratings.
- ▾Below 50-day MA (-9.32%)
- ▸~64% upside to price target
Is BMRN a buy right now?
Trend: BMRN is trading below the 50-day average (-9.32%), RSI 59 — neutral momentum, with a 3-month return of -10.18%.
Valuation & quality: BioMarin Pharmaceutical Inc. trades on a trailing P/E of 150.7, forward P/E 8.4, PEG 0.33, price-to-book 1.71; fundamentals show net margin 2.1%, return on equity 1.2%, revenue growth 19.9% year on year.
Analyst consensus: 27 analysts have a mean 12-month price target of $91.56 (+64.2% vs the last close; range $60.00 – $122.00), consensus rating “buy”.
Our screen: BUY (score 3) — Rare-disease portfolio and strong analyst upside support attractive six-to-twelve-month appreciation potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -8.50% | -4.60% | +6.30% | -0.10% | +4.90% | +8.70% | -8.00% | -7.10% |
Fundamentals
Analyst price target
Technical signals
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Sector: Healthcare · Industry: Biotechnology · United States · 3,221 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.